Ultragenyx Receives FDA Breakthrough Therapy Designation For Setrusumab (UX143) To Reduce Fracture Risk In Osteogenesis Imperfecta Types I, III, And IV For Patients Aged 2 And Older
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx has received FDA Breakthrough Therapy Designation for Setrusumab (UX143) aimed at reducing fracture risk in patients with Osteogenesis Imperfecta Types I, III, and IV, aged 2 and older.
October 07, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ultragenyx's Setrusumab (UX143) has been granted FDA Breakthrough Therapy Designation, which could accelerate its development and approval process. This designation is for reducing fracture risk in Osteogenesis Imperfecta patients aged 2 and older.
The FDA Breakthrough Therapy Designation is significant as it can expedite the development and review process of Setrusumab, potentially leading to earlier market entry. This is likely to positively impact Ultragenyx's stock price in the short term as it enhances the company's product pipeline and growth prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100